2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Polycystic Ovary Syndrome
1
Overweight
1
Obesity
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
pembrolizumab
1032
Carboplatin
969
Paclitaxel
942
Gemcitabine
799
Cisplatin
755
Docetaxel
698
Bevacizumab
638
Nivolumab
520
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
471
Fluorouracil
425
Dexamethasone
410
Rituximab
391
Oxaliplatin
352
Injections
345
Trastuzumab
313
atezolizumab
311
Cetuximab
291
Leucovorin
289
Irinotecan
271
130-nm albumin-bound paclitaxel
256
Prednisone
251
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
217
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
licogliflozin
×
Clear all
NCT03152591
2021-01-05
PCOS
Novartis
Phase 2
Completed
29 enrolled
24 charts